ZENFLOW, INC.

SOUTH SAN FRANCISCO, CA · Founded 2014 · Medtech · Private

A single-wire nitinol coil implant with transurethral delivery system for treating benign prostatic hyperplasia

Claim this profile

Follows are private to you and power your alerts

Updated · zenflow.com

Sector
Medtech
Headquarters
SOUTH SAN FRANCISCO, CA
Founded
2014
Latest Form D
$19.4M, Nov 2024
Total capital
$57.5M
Federal grants
$3.4M
5 awards · 2015–2020
Rank in peer group#285 of 538
Private capital raised
$54.1M
3 Form D · last Nov 2024
23 months since last filing
Federal contracts
None on recordNo federal contract awards found.
Granted patents
12
22 pending · first 2021
Rank in peer group#51 of 538

Capital timeline

20152017201920212023FEDERAL ↑EQUITY ↓Cumulative $57.5M$180K$1.3M$637K$714K$557K1st Form D$11M2nd Form D$23.7M3rd Form D$19.4M
20152017201920212023FEDERAL ↑EQUITY ↓Cumulative $57.5M$1.3M$637K$714K$557K1st Form D$11M2nd Form D$23.7M

Latest events

  • Private capital raisedForm D · SEC · 3rd filing$19.4M
  • Private capital raisedForm D · SEC · 2nd filing$23.7M
  • Federal grantHealth and Human S · Phase II · Improvement and validation of the Spring System for Permanent Relief of Urinary Obstruction related to Benign Prostatic Hyperplasia (BPH)$557K
  • Federal grantHealth and Human S · Phase II · Improvement and validation of the Spring System for Permanent Relief of Urinary Obstruction related to Benign Prostatic Hyperplasia (BPH)$714K
  • Federal grantHealth and Human S · Phase II · Spring System for Permanent Relief of Urinary Obstruction related to Benign Prostatic Hyperplasia$637K
  • Private capital raisedForm D · SEC · 1st filing$11M
  • Federal grantHealth and Human S · Phase II · Spring System for Permanent Relief of Urinary Obstruction related to Benign Prostatic Hyperplasia$1.3M
Show 1 earlier federal award
  • Federal grantNSF · Phase I · SBIR Phase I: Development of a device for permanent relief of urinary obstruction related to benign prostatic hyperplasia$180K

Node area is scaled to amount. Form D reports securities sold, which can differ from an announced round; filings are numbered in the order they were made.

Federal first

27months

from ZENFLOW, INC.’s first federal award to its first private round.

First federal award · Jun 2015
NSF · $180K
First Form D · Oct 2017
$11M · 1st Form D
Awards before first raise
2 awards

An association in public records, not a cause or a prediction.

Standing among 538 peers

Line = median

Medtech · Device

  • Federal grantsBelow median
  • Granted patents#51 · top 9%

Cumulative measures favor older companies. Rankings describe position today, not outcome. Below the median, ranks show as a band rather than a number.

Founders and team

Researcher links verified by same-company patents and grants
  • Shreya MehtaResearcherExecutive Officer, DirectorLinked by 1 patent
  • Nicholas DamianoResearcherExecutive Officer, DirectorLinked by $3.4M in grants as PI
  • Andrew CleelandDirectorNamed in SEC Form D filings
  • Blayne RoederDirectorNamed in SEC Form D filings
  • Bryan KimDirectorNamed in SEC Form D filings
  • John BeckExecutive OfficerNamed in SEC Form D filings
Show all 10 people
  • Nick DamianoExecutive Officer, DirectorNamed in SEC Form D filings
  • Radu CautisDirectorNamed in SEC Form D filings
  • Robert WeisskoffDirectorNamed in SEC Form D filings
  • Susan StimsonDirectorNamed in SEC Form D filings

What it has protected

USPTO · 12 granted of 34
Show all 34 patent records

Regulatory activity · Medtech

Sector-level, not company-level

Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.

Sources

Federal grants from SBIR/STTR, NIH, NSF and DoD records. Federal contracts from USAspending.gov. Private capital from SEC Form D. Patents from USPTO. Publications from OpenAlex. Regulatory activity from the Federal Register. Press matched on company name.

How to read this page

Figures show associations in public records, not causes or predictions. Nothing here is investment advice. An em-dash means no record was found under this company's name, not that none exists.

Data freshness

SEC Form D filings through . SBIR and STTR awards through .